Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis

被引:9
|
作者
Concha-Velasco, Fatima [1 ,2 ]
Gonzalez-Lagos, Elsa [1 ,2 ]
Seas, Carlos [1 ,2 ,3 ]
Bustamante, Beatriz [1 ,3 ]
机构
[1] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru
[2] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru
[3] Hosp Cayetano Heredia, Dept Enfermedades Infecciosas Trop & Dermatol, Lima, Peru
来源
PLOS ONE | 2017年 / 12卷 / 03期
关键词
HIGH-DOSE FLUCONAZOLE; EARLY FUNGICIDAL ACTIVITY; AMPHOTERICIN-B; RANDOMIZED-TRIAL; COMBINED COHORT; FUNGAL BURDEN; COMBINATION; AIDS; MORTALITY; FLUCYTOSINE;
D O I
10.1371/journal.pone.0174459
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction The first-line combination therapy for HIV-associated cryptococcal meningitis (CM), a condition of high mortality particularly in the first two weeks of treatment, consists of amphotericin B plus flucytosine (5-FC). Given that 5-FC remains unavailable in many countries, the knowledge of factors influencing mycological clearance in patients treated with second-line therapy could contribute to effective management. Objectives To determine the factors associated with the clearance of Cryptococcus sp. from the cerebrospinal fluid by the second week of effective antifungal therapy (early mycological clearance) in HIV-associated CM. Methods 0Retrospective cohort study based on secondary data corresponding to HIV-associated CM cases hospitalized at a tertiary health care center in Lima, Peru where 5-FC remains unavailable. Risk factors associated with early mycological clearance were analyzed by generalized linear regression models. Results From January 2000 to December 2013, 234 individuals were discharged with a diagnosis of HIV-associated CM; in 215 we retrieved the required data. The inpatient mortality was 20% (43/215), 15 of them in the first two weeks of treatment. In the final model (157 cases), adjusted for age, previous episode of CM, ART use, type of antifungal treatment, raised intracranial pressure, frequency of therapeutic lumbar punctures, baseline fungal burden and treatment period, the factors associated with early mycological clearance were: Amphotericin B deoxycholate plus fluconazole as combination therapy (RR, 1.56; 95% CI, 1.14-2.14); severe baseline intracranial pressure (>= 35 cm H2O) (RR, 0.57; 95% CI, 0.33-0.99); and baseline fungal burden over 4.5 log(10) CFU/mL (RR, 0.61 95% CI: 0.39-0.95). Conclusions In a setting without access to first-line therapy for CM, the combination therapy with amphotericin B deoxycholate plus fluconazole was positively associated with early mycological clearance, while high fungal burden and severe baseline intracranial pressure were negatively associated, and thus related to failure.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
    Qi, Tangkai
    Chen, Fang
    Ma, Siyue
    Zhang, Renfang
    Liu, Li
    Wang, Zhenyan
    Tang, Yang
    Song, Wei
    Sun, Jianjun
    Yang, Junyang
    Xu, Shuibao
    Zhao, Bihe
    Shen, Yinzhong
    Chen, Jun
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (06) : 1667 - 1675
  • [22] Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa
    Temfack, Elvis
    Lortholary, Olivier
    LANCET INFECTIOUS DISEASES, 2022, 22 (09): : 1262 - 1264
  • [23] Analysis of intracranial lesions in patients with HIV-associated cryptococcal meningitis
    Song, Wei
    Liu, Li
    Qi, Tangkai
    Wang, Zhenyan
    Tang, Yang
    Sun, Jianjun
    Xu, Shuibao
    Yang, Junyang
    Wang, Jiangrong
    Chen, Jun
    Zhang, Renfang
    Shen, Yinzhong
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2025, 15
  • [24] The evolution of HIV-associated cryptococcal meningitis in Uganda from 2010 to 2022
    Walukaga, Stewart
    Fieberg, Ann
    Musubire, Abdu
    Tugume, Lillian
    Ssebambulidde, Kenneth
    Kagimu, Enock
    Kasibante, John
    Rutakingirwa, Morris K.
    Mpoza, Edward
    Gakuru, Jane
    Akampurira, Andrew
    Jjunju, Samuel
    Mwesigye, James
    Muzoora, Conrad
    Nuwagira, Edwin
    Bangdiwala, Ananta S.
    Williams, Darlisha A.
    Rhein, Joshua
    Meya, David B.
    Boulware, David R.
    Hullsiek, Kathy Huppler
    Rajasingham, Radha
    ASTRO Team, Jane Francis
    MEDICAL MYCOLOGY, 2025, 63 (01)
  • [25] Combination Therapy for HIV-Associated Cryptococcal Meningitis-A Success Story
    Hurt, William J.
    Harrison, Thomas S.
    Molloy, Sile F.
    Bicanic, Tihana A.
    JOURNAL OF FUNGI, 2021, 7 (12)
  • [26] An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies
    Shapiro, Adrienne E.
    Tenforde, Mark W.
    Chiller, Tom M.
    Ford, Nathan
    Rajasingham, Radha
    HIV MEDICINE, 2023, 24 (04) : 507 - 512
  • [27] Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
    Rajasingham, Radha
    Smith, Rachel M.
    Park, Benjamin J.
    Jarvis, Joseph N.
    Govender, Nelesh P.
    Chiller, Tom M.
    Denning, David W.
    Loyse, Angela
    Boulware, David R.
    LANCET INFECTIOUS DISEASES, 2017, 17 (08): : 873 - 881
  • [28] Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
    Brouwer, AE
    Rajanuwong, A
    Chierakul, W
    Griffin, GE
    Larsen, RA
    White, NJ
    Harrison, TS
    LANCET, 2004, 363 (9423): : 1764 - 1767
  • [29] Preventing death from HIV-associated cryptococcal meningitis: The way forward
    Roy M.
    Chiller T.M.
    Current Fungal Infection Reports, 2011, 5 (4) : 206 - 214
  • [30] Ventriculo-peritoneal shunting in the management of HIV-associated cryptococcal meningitis
    Asnis, Deborah
    Febles, Taynet
    Kapoor, Anil
    Di John, David
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (05): : 225 - 225